We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Prir is a new premium functional soft drink that not only provides a great tasting, healthier way to hydrate but also gives you the valuable nutrition you need to help maintain healthy skin, hair and nails. Prir is currently stocked in over 300 Boots stores nationwide and is also available in the boots meal deal.
days to go: Expired investment: £12,770
Business Finance Market (BFM) is a financial technology platform that stimulates the market towards Small and Medium Enterprises (SMEs) lending via data in the UK. BFM claims that SMEs are gradually being excluded from mainstream banking. The company cites that in 1988, 40% of all bank lending went to SMEs. BFM points out that lending today is closer to 4% with an estimated £22 billion funding gap to the 5.9 million UK SMEs. BFM asserts that almost 90% of SME loan applications are stuck due to a lack of choice and transparency when it comes to securing finance. BFM aspires to solve this dilemma. It states that its technology allows SMEs to experience quicker finance decisions based on true addressable market access and allows lenders and intermediaries access to its platform to help manage the end-to-end application process, improve deal flow, and deliver faster credit decisions. BFM intends to exit via a trade sale within the financial sector.
days to go: Expired investment: Withheld
Kalendit removes the middleman (agencies) and provides UK nurseries with temporary staff while helping them save up to 50% on staffing fees. Since September, over 150 users joined Kalendit, and it is continuing to add about two workers daily. This company had launched its services in November with four nurseries, and since then, have been successfully processed 49 bookings. With the funds raised, it will hire people and serve thirty nurseries in one year.  By the fifth year, it wants to take 45% of the London market, which equates to 1400 nurseries.
days to go: Expired investment: £82,180
Phrooti is a fruit tea that is made up of 95-97% real fruit and 3-5% natural flavouring. It is designed to be a healthier and fruitier alternative to the current teas on the market. Phrooti is caffeine-free, gluten-free, dairy-free, low calorie and has no added sugar.
days to go: Expired investment: £11,740
TeaTime deliver fresh and healthy tea blends straight to your door. Simply choose how often you wish to receive your box, weekly or fortnightly and TeaTime will dispatch a selection of 4 of their blends out to you within 48 hours.
days to go: Expired investment: £18,940
With new MiFID II regulations introduced in January, Hiddensee provides independent investment research mainly on forensic accounting and corporate governance. Analysts will search for inconsistencies and anomalies in the valuation of UK listed mid-cap and smaller companies and publish their reports to assist investors in deciding whether to buy or sell shares.
days to go: Expired investment: £143,097
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph